ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

ACS Community Demonstration Projects Complete, Reach Target Populations, Teach Many Lessons

June 25, 1993

FDA Approves Gleevec In 73 Days, A Speed Record.

May 18, 2001

Clinical Oncology Program Overview Updates Ongoing Trials

December 8, 1989

In Brief: NY Judges, Lawyers Form Breast Cancer Alert; Terms of ODAC Chairman, 3 Members Expire

July 3, 1992

NCI Bypass Budget For FY99 Proposes Expansion of Cancer Clinical Trials System

December 5, 1997

Amgen, J&J Defend ESA Indications.

March 21, 2008